Protein Kinase C Beta II Peptide Inhibitor Elicits Robust Effects on Attenuating Myocardial Ischemia/Reperfusion Injury
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Introduction

Hypothesis

Heart disease remains the leading cause of death in adults in the United States and
worldwide, with coronary artery disease being the most common form that often leads to a
myocardial infarction. While rapid restoration of coronary blood flow is crucial to
preserving cardiac tissue function, it also results in an additional insult known as
myocardial ischemia/reperfusion (MI/R) injury. MI/R injury may be attenuated by
inhibiting the generation of reactive oxygen species (ROS) upon cardio-angioplasty
following a heart attack. Protein kinase C beta II (PKCβII) generates ROS during
reperfusion via cytokine receptor activation (Figure 1) (1). Activated PKCβII (via Ca2+
and second messenger diacylgylcerol) binds to its selective receptor for activated C kinase
(RACK). RACK enhances PKCβII translocation to the cell membrane and its interaction
with substrates, like NADPH oxidase (NOX-2) (2). PKCβII phosphorylates and activates
NOX-2 which then generates ROS (Figure 2) (3,4).

Of the many proteins that PKCβII phosphorylates, for the purposes of this study, we believe
NOX-2 phosphorylation is a key pathway in the ROS mediated damage in MI/R injury.
Thus, we hypothesize that myr-PKCβII- will reduce infarct size and improve postreperfused cardiac function as compared to non-drug treated controls, whereas myrPKCβII+ treated hearts will not improve these parameters.

Figure 1. . Schematic representation
of PKCβII mediated activation of
mitochondrial reactive oxygen
species (ROS) and NADPH oxidase
superoxide (O2-) release and
decreased NO release from eNOS in
MI/R (adapted from [5,6]). MI/R
induces cytokine receptor activation
leading to activation of PKC βII via
diacylglycerol (DAG). Activated
PKCβII increases ROS and O2release from damaged mitochondria
and NADPH oxidase, respectively,
and decreases eNOS activity. It also
stimulates mitochondrial p66Shc
protein, a component in the pathway
resulting in opening of the
mitochondrial permeability transition
pore (PTP), which in turn leads to
release of proapoptotic factors into
the cytosol to further promote tissue
injury during reperfusion.

Inhibition of tissue NOX-2 attenuates inflammation mediated vascular injury seen in various
diseases, including diabetes and myocardial infarction (4). Previously, a myristoylated (myr-)
selective PKCβII peptide inhibitor (N-myr-SLNPEWNET; myr-PKCβII-) was found to dose
dependently inhibit superoxide (SO) release and MI/R injury via the mechanism depicted in
Figure 2 (3, 6, 7). Myristoylation of peptides is known to potentiate their entry into the cell
via simple diffusion through the cell membrane to affect PKC activity (8). However, the
effect of myr-PKCβII peptide activator (N-myr-SVEIWD; myr-PKCβII+) on MI/R injury has
not been studied (9).

Research Design
Male Sprague-Dawley rats (~300g, Charles River, Springfield, MA) were anesthetized with
I.P. pentobarbital (60mg/kg) and anticoagulated with 1000U of heparin. The heart was then
removed and placed on the perfusion needle of the Langendorff apparatus. A pressure
transducer was placed into the left ventricle to measure cardiac function, as previously
described (6,7).
A schematic of the MI/R protocol is depicted below:
myr-PKCβII+/(20μM) first
5min.

Baseline
(15min.)

Ischemia
(30min.)

Reperfusion
(50min.)

TTC
staining

At the end of the reperfusion period, all hearts were frozen at -20 oC for 30 min, sectioned
into 2mm slices and incubated at 37oC in 1% triphenyltetrazolium chloride (TTC). The
percentage between dead heart tissue (i.e., unstained) weight to total heart tissue weight
was calculated for infarct size.
Statistical Analysis
All data in the text, figures, and table are presented as means ± S.E.M. The data were
analyzed by ANOVA using the Fisher’s PLSD test. Probability values of <0.05 are
considered to be statistically significant.

Results

Table 1. Initial and final cardiac function values and infarct size for control, myr-PKCβII+/- MI/R studies; *p<0.05, **p<0.01 vs.
non-drug treated controls; #p<0.05, ##p<0.01 vs. myr-PKCβII+. Representative sections shown are both sides of a 2mm mid-wall
section for each MI/R study group. +dP/dt max = contractility, -dP/dt min = relaxation, LVDP = left ventricular developed pressure,
LVESP = left ventricular end systolic pressure, LVEDP = left ventricular end diastolic pressure.

Cardiac Function and
Infarct Size Indices

Control (n= 9)

PKCβ Inhibitor (n=8)

PKCβ Activator (n=9)

Initial Flow (mL/min)

20±2

17±1

18±2

Final Flow (mL/min)

10±1

10±1

11±2

Initial +dP/dtmax
(mmHg/sec)

2428±81

2316±48

2430±65

Final +dP/dtmax
(mmHg/sec)

906±137

1585±165**##

989±161

Initial -dP/dtmin
(mmHg/sec)

-1685±87

-1637±46

-1630±76

Final -dP/dtmin
(mmHg/sec)

-855±118

-1048±121*#

-814±103

Initial LVDP (mmHg)

96±3

89±2

91±3

Final LVDP (mmHg)

48±9

67±7*##

43±7

Initial LVESP (mmHg)

105±4

98±2

98±3

Final LVESP (mmHg)

106±5

104±5

104±3

Initial LVEDP (mmHg)

9±1

8±1

7±1

Final LVEDP (mmHg)

58±5

37±7**##

58±4

Initial Heart Rate
(BPM)

273±5

276±8

280±10

Final Heart Rate
(BPM)

258±8

247±5

246±8

Infarct Size (%)

26±5

14±3*

25±3

Representative
Sections

Conclusions
Infarct size
Myr-PKCβII- treated hearts had significantly reduced infarct size compared to controls. We
believe there was no significant difference between myr-PKCβII- and myr-PKCβII+ because
NOX-2 mediated ROS generation during reperfusion may be maximally activated by tissue
cytokines and further stimulation by myr-PKCβII+ does not result in additional tissue injury.
Cardiac function
Myr-PKCβII- improved post-reperfused cardiac function (vs. both control and myr-PKCβII+).
The significant improvement in final post-reperfusion LVDP in myr-PKCβII- treated hearts is
attributed to the significant reduction in final LVEDP values (i.e. ~37mmHg) compared to
control and myr-PKCβII+ hearts (i.e. ~58mmHg), and is reflected in the significant restoration
of the final maximal rate of contractility (+dP/dtmax) and relaxation (-dP/dtmin).
These results suggest that: 1) Inhibition of myocardial tissue NOX-2 activity may be the
principal pathway through which myr-PKCβII- mediates its cardio-protective effects in MI/R
injury. 2) Treatment with myr-PKCβII- would be an effective strategy to limit MI/R injury in
heart attack patients upon reperfusion via fibrinolytic therapy, angioplasty or coronary artery
bypass surgery.
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Figure 2. Schematic representation of PKCβII peptides. PKCβII+ and PKCβII- both bind to the Ca2+
binding domain within the RACK binding site (i.e., C2-4 region;) of PKCβII to regulate its translocation
to the cell membrane (top; Adapted from [3]). PKCβII+ mechanism of action is to increase PKCβII
translocation to the cell membrane via RACK binding and its interaction with substrates, like NOX-2,
while PKCβII- inhibits that interaction (bottom; Adapted from [2]).

Figure 3. Time course of left ventricular developed pressure (LVDP) for control, myr-PKCβII+/- MI/R studies.
Myr-PKCβII- treated hearts showed a trend to improve LVDP after the first five minutes of reperfusion and this
trend was exhibited throughout the 50 minute reperfusion time course. This was significantly different from both
control and myr-PKCβII+ treated hearts during the reperfusion period. *p<0.05 vs. non-drug treated controls,
##p<0.01 vs. myr-PKCβII+.
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